



28 **Summary**

29 Bile acids (BAs) facilitate intestinal fat absorption and act as important signaling  
30 molecules in host-gut microbiota crosstalk. BA-metabolizing pathways in the  
31 microbial community have been identified, but how the highly variable genomes of  
32 gut bacteria interact with host BA metabolism remains largely unknown. We  
33 characterized 8,282 structural variants (SVs) of 55 bacterial species in the gut  
34 microbiomes of 1,437 individuals from two Dutch cohorts and performed a systematic  
35 association study with 39 plasma BA parameters. Both variations in SV-based  
36 continuous genetic makeup and discrete subspecies showed correlations with BA  
37 metabolism. Metagenome-wide association analysis identified 797 replicable  
38 associations between bacterial SVs and BAs and SV regulators that mediate the  
39 effects of lifestyle factors on BA metabolism. This is the first large-scale microbial  
40 genetic association analysis to demonstrate the impact of bacterial SVs on human BA  
41 composition, and highlights the potential of targeting gut microbiota to regulate BA  
42 metabolism through lifestyle intervention.

43

44 **Keywords:** Human gut microbiome, bile acid metabolism, bacterial genetics,  
45 structural variation

46

47

## 48 **Introduction**

49 Bile acids (BAs) represent an important class of biologically-active metabolites that  
50 act at the interface between host and gut microbiota. BAs are amphiphilic steroids  
51 synthesized from cholesterol in the liver and are well-known for their roles in  
52 facilitating intestinal fat absorption, promoting hepatic bile formation and maintaining  
53 whole-body cholesterol balance. In addition, BAs exert hormone-like functions by  
54 signaling via membrane-bound and nuclear receptors involved in the control of lipid,  
55 glucose and energy metabolism (Kuipers et al., 2014). Altered BA metabolism has  
56 been associated with several metabolic diseases, including type 2 diabetes (T2D) and  
57 non-alcoholic fatty liver disease (NAFLD) (Chávez-Talavera et al., 2017), and with  
58 colorectal cancer (Dermadi et al., 2017) and hepatocellular carcinoma (Gao et al.,  
59 2019).

60 Gut bacteria are essential players in human BA metabolism: bacterial bile salt  
61 hydrolases (BSH) convert the glycine- and taurine-conjugated primary BAs produced  
62 by the liver (cholic (CA) and chenodeoxycholic (CDCA) acids) into unconjugated  
63 primary BAs that can subsequently be dehydroxylated to form secondary BAs  
64 (deoxycholic (DCA) and lithocholic (LCA) acids) (Jia et al., 2017). Secondary BAs  
65 are efficiently absorbed in the ileum and, to a lesser extent the colon, and return to the  
66 liver via the portal venous system for re-secretion into the bile. Consequently, the BA  
67 pool consists of a mixture of primary and secondary BAs that travel between liver and  
68 intestine within the enterohepatic circulation. Recent cohort studies have  
69 demonstrated remarkable inter-individual variation in the human BA pool  
70 composition, as inferred by analyzing BA composition in peripheral blood from both  
71 healthy (Steiner et al., 2011) and obese subjects (Chen et al., 2020). Importantly, this  
72 variability could largely be attributed to metabolic and transport processes within the  
73 enterohepatic circulation rather than to differences in hepatic synthesis rates, implying  
74 a key role for the microbiome in BA diversity (Chen et al., 2020).

75 In recent years, we have learned a great deal about the large variability of  
76 microbial composition in healthy humans and compositional alterations associated  
77 with specific diseases (Falony et al., 2016; Jackson et al., 2018; Zhernakova et al.,  
78 2016). The relationships between host BA pool and gut microbial composition were  
79 also investigated in several cohorts with differing health status. For instance, in  
80 untreated T2D patients, concentrations of plasma glycochenodeoxycholic acid

81 (GUDCA), LCA and DCA were associated with the overall composition of gut  
82 microbiome (Gu et al., 2017). In the 300OB obesity cohort, a considerable number of  
83 associations were identified between the relative abundances of gut bacteria and BA  
84 parameters in feces and plasma (Chen et al., 2020). Many bacterial genes involved in  
85 BA biotransformation have been identified through experimental and homologue-  
86 based bioinformatic approaches. For instance, the BSH gene pool has been quantified  
87 and characterized in the metagenomes of diverse populations (Song et al., 2019).  
88 Based on the catalog of known BA-related genes present in gut bacterial genomes, the  
89 BA biotransformation potential of individuals can be predicted using metabolic model  
90 reconstructions (Heinken et al., 2019).

91 However, abundance-based analyses commonly assess taxa abundance at genus-  
92 or species-level, and the interaction of genetic diversity with BA metabolism within  
93 species has not yet been properly addressed. Since the functionality of a considerable  
94 proportion of microbial genes is still unknown (Heintz-Buschart and Wilmes, 2018),  
95 the homologue-based method for microbial BA gene analysis, which relies on the  
96 known references of BA biotransformation genes, has limited our understanding of  
97 the interactions of BAs with the “dark matter” of the gut microbiome. In addition, the  
98 accuracy of *in silico* modeling of BA biotransformations is affected by the possibility  
99 of undiscovered pathways in BA modification. Importantly, BAs themselves also  
100 influence gut microbiome composition through their antimicrobial activities and via  
101 indirect signaling pathways (Jia et al., 2017). However, the overall genetic shift of gut  
102 bacteria due to their exposure to the various BAs present in the human BA pool is  
103 currently unknown. This motivated us to explore the relationships between the gut  
104 microbiome and host BA metabolism at the level of microbial genetics.

105 Microbial structural variants (SVs) are highly variable segments of bacterial  
106 genomes that have been defined in recent years based on metagenomic sequencing  
107 data (Zeevi et al., 2019). Microbial SV regions potentially contain functional genes  
108 involved in host-microbe interactions and could thus provide information on sub-  
109 genome resolution of bacterial functionality. A variety of associations have been  
110 found between SVs and metabolite levels in human blood (Zeevi et al., 2019).  
111 Recently, a longitudinal study comparing subjects with irritable bowel syndrome to  
112 healthy individuals reported associations between BAs and microbial SVs for the first  
113 time (Mars et al., 2020). In this study, fecal levels of two unconjugated primary BA

114 species, CDCA and CA, were found to correlate with variable genomic segments of  
115 *Blautia wexlerae*. This finding provided the initial clue that previously unknown  
116 bacterial genes are involved in the modification of primary BAs or indirectly associate  
117 with host BA metabolism (Mars et al., 2020). However, in view of the limited sample  
118 size and number of individual BA species analyzed in this study and the unknown  
119 reproducibility of the associations between SVs and BAs across different cohorts,  
120 systematic analysis in large-scale, population-based cohorts is required. Moreover,  
121 although the BA-associated SVs were interpreted as potential BA-metabolizing  
122 genomic segments (Mars et al., 2020), the existence of a causal relationship between  
123 BAs and microbial variants remains to be established because BAs can also act as  
124 regulators of the gut microbiome.

125 We therefore aimed to systematically evaluate the relationships between several  
126 parameters of human BA metabolism and the genetic architecture of the gut  
127 microbiome based on SVs. This study involved 1,437 individuals from two  
128 independent Dutch cohorts: the population-based Lifelines-DEEP cohort (LLD,  $N =$   
129 1,135) (Tigchelaar et al., 2015) and the 300-Obesity cohort (300-OB,  $N = 302$ ) (Horst  
130 et al., 2019). In both cohorts, we profiled fasting plasma levels of 15 different BA  
131 species and 7 $\alpha$ -hydroxy-4-cholesten-3-one (C4), which reflects the hepatic synthesis  
132 rate of BAs. We also calculated the relative proportions of individual BAs as well as  
133 different BA concentration ratios that represent metabolic pathways and enzymatic  
134 reactions. In all, we obtained 39 BA-related parameters. Simultaneously, the  
135 metagenomics sequencing data was subjected to characterization of microbial SVs to  
136 generate variable SV (vSV) and deletion SV (dSV) profiles that represent the  
137 standardized coverage and presence/ absence status of genomic segments,  
138 respectively. We then performed a systematic microbial genetic association analysis  
139 of BAs, not only with individual SVs, but also with discrete strains and the  
140 continuous genetic structures defined by the SV profiles. We further integrated  
141 several lifestyle factors, including diet, drug usage and smoking, and constructed  
142 tripartite networks of *in silico*-inferred causal relationships that included exposures,  
143 microbial genetics and host plasma BA composition. This identified potential novel  
144 microbial genetic regulators that mediate the effect of lifestyle on BA metabolism,  
145 which supports the potential of targeting the gut microbiome to alter human BA  
146 metabolism.

147

148

## 149 Results

### 150 High variability of plasma BA composition between individuals and cohorts

151 We included 1,437 individuals from two independent Dutch cohorts in this study:  
152 1,135 individuals from the population-based LLD cohort and 302 individuals from the  
153 obese elderly-targeted 300-OB cohort (**Figure 1A-C; Table S1**). We assessed the  
154 concentrations and proportions of 15 BA species (6 primary and 9 secondary BAs) in  
155 fasting plasma: cholic acid (CA), chenodeoxycholic acid (CDCA), lithocholic acid  
156 (LCA), deoxycholic acid (DCA), ursodeoxycholic acid (UDCA) and their glycine- or  
157 taurine-conjugated forms (**Table S2**). We also computed 8 ratios that reflect hepatic  
158 and bacterial enzymatic activities (**Table S2; STAR Methods**) and quantified the  
159 plasma level of C4, a biomarker of hepatic BA biosynthesis (Chiang, 2017). In total,  
160 we obtained 39 plasma BA parameters in this study.

161 Both the concentrations and proportions of the 15 BA species showed  
162 considerable inter-individual variation in both cohorts (**Figure 1D and 1E**). For  
163 instance, the total plasma BA concentration ranged from 0.084 to 18.008  $\mu\text{M}$  (**Figure**  
164 **1D; Table S3**) and the secondary/primary BA ratio ranged from 0 to 10.13 across all  
165 samples (**Figure 1E; Table S3**). Principal coordinate analysis (PCoA) also showed  
166 significant differences in plasma BA composition between LLD and 300-OB  
167 (Permutational multivariate analysis of variance (PERMANOVA),  $P = 0.001$  in BA  
168 concentration profile,  $P = 0.001$  in BA proportion profile; **Figure 1F and 1G**). We  
169 also observed that 34 of the 39 BA parameters showed significant differences between  
170 LLD and 300-OB (Wilcoxon rank-sum test,  $\text{FDR} < 0.05$ ; **Figure S1A; Table S4**). In  
171 view of the distinctly different characteristics of participants between LLD and 300-  
172 OB (**Figure 1A-1C**), the difference in BA composition between the two cohorts could  
173 be caused by phenotypic differences. We therefore estimated the explanatory power  
174 of basic phenotypes such as age, sex and body mass index (BMI) on the variation in  
175 BA composition. These factors collectively explained only 3.07% and 2.94% of the  
176 variance in plasma BA concentration and BA proportion profiles, respectively  
177 (**Figure 1H and 1I**). Here, age had the largest effect, explaining 1.66% and 1.74% of  
178 the variance in plasma BA concentration and proportion profiles, respectively  
179 (PERMANOVA,  $p < 0.05$ ; **Figure 1H and 1I**). This suggests that a large proportion  
180 of BA variation remains unexplained and may be attributed to other factors such as

181 lifestyle factors, host genetic background and gut microbial factors.

182 **SV profiling unravels microbial genetic differences between the general**  
183 **population-based and the obesity-based cohorts**

184 Using the metagenomics sequencing data from both cohorts, we detected 8,282 SVs,  
185 including 2,616 vSVs and 5,666 dSVs in 55 species that were present in at least 75  
186 samples in the two cohorts with sufficient coverage across the reference genomes  
187 (STAR<sup>2</sup>Methods) with 32–374 SVs per species (Figure 2A and 2B; Table S4).  
188 These 55 species together accounted, on average, for 66.60% of the total microbial  
189 species composition, ranging from 27.02%–90.25% (Figure S2A). The average  
190 sample size of all 55 species with SVs was 432 (Figure S2B; Table S5). The most  
191 prevalent species with SV calling was *B. wexlerae*, which could be detected in 1,350  
192 samples (1,071 from LLD and 279 from 300-OB), followed by *E. rectale* ( $N = 1,160$ ),  
193 *E. hallii* ( $N = 1,138$ ) and *Ruminococcus* sp. ( $N = 1,095$ ).

194 We further assessed the Canberra distance of bacterial SV profiles between all  
195 samples (Figure 2C). Principal components (PCo) 1 and 2 together explained 20.70%  
196 of the total SV-based genetic variance (Figure 2C), which showed significant  
197 differences between LLD and 300-OB (Wilcoxon rank-sum test,  $P = 9.83 \times 10^{-4}$  for  
198 PCo1 and  $P = 2.62 \times 10^{-11}$  for PCo2), indicating the divergence of microbial genetics  
199 between the general population-based cohort and the obesity cohort. Interestingly, age,  
200 gender, BMI and read counts collectively only explained 1.79% of the variance of the  
201 metagenome-wide SV profile (Figure S2C), while the top factor, total read counts,  
202 explained only 0.7% of the variation.

203 **Species-level genetic makeup correlates with human BA metabolism independent**  
204 **of bacterial species abundance**

205 We first investigated the taxonomic abundance and microbial genetic associations  
206 with fasting plasma BA parameters separately at the species level (Figure S3A and  
207 S3B). In total, we identified 226 significant associations between the relative  
208 abundance of 34 bacterial species and 36 BA parameters (Linear regression,  
209  $FDR_{Meta} < 0.05$ ; Figure S3B; Table S6). Several BA parameter-associated species had  
210 been reported earlier in the 300-OB cohort, e.g. the negative association of the relative

211 abundance of the butyrate-producing species *F. prausnitzii* with 20 BA parameters,  
212 including a negative association with secondary/primary BA ratio (Linear regression,  
213  $\text{Beta}_{\text{Meta}}=-0.18$ ,  $\text{FDR}_{\text{Meta}}=3.97 \times 10^{-6}$ ; **Table S6**). The relative abundance of another  
214 butyrate-producing species, *E. hallii*, correlated with C4 concentration (Linear  
215 regression,  $\text{Beta}_{\text{Meta}}=0.10$ ,  $\text{FDR}_{\text{Meta}}=4.72 \times 10^{-3}$ ; **Table S6**), consistent with findings  
216 from a mouse study showing that *E. hallii* is able to modify BA metabolism  
217 (Udayappan et al., 2016). The most significant abundance association was found  
218 between *R. gnavus* and UDCA proportion in plasma (Linear regression,  $\text{Beta}_{\text{Meta}}=0.34$ ,  
219  $\text{FDR}_{\text{Meta}}=7.77 \times 10^{-28}$ ; **Table S6**). Altogether, these results confirm that microbiome  
220 composition is closely associated with human BA metabolism.

221 As bacterial genomes are highly variable, the microbial genetic content of each  
222 species varies across different individuals (Rossum et al., 2020; Tierney et al., 2019),  
223 which may also be relevant to human BA metabolism. Therefore, we first calculated  
224 the SV-based genetic distance per species (**Figure S4**) and associated these with the  
225 39 plasma BA parameters using PERMANOVA, after correcting for age, sex, BMI,  
226 read counts and species abundance if applicable (**STAR Methods**). In total, we  
227 identified 260 significant associations between genetic distances of 39 bacterial  
228 species and 36 BA parameters (PERMANOVA,  $\text{FDR}_{\text{Meta}} < 0.05$ ; **Figure S3A**; **Table**  
229 **S6**), which indicates that SV-represented microbial genetic associations with BA  
230 parameters are largely independent of the relative abundances of the species.  
231 Interestingly, some species were found to be more likely associated with BA  
232 parameters at the genetic level (e.g. *C. comes*, *E. rectale* and *R. intestinalis*), whereas  
233 other species tended to be associated with BA parameters at the relative abundance  
234 level (e.g. *A. muciniphila*, *B. bifidum*, *B. crossotus* and *I. bartlettii*) (**Figure 3A**). Out  
235 of 260 BA associations with species-specific genetic makeup, only 50 were also  
236 detected at the species abundance level (**Figure S3C**; **Figure 3A**), which highlights  
237 that microbial genetic variation represents a new layer of information about bacterial  
238 functionality.

239 The species with the highest number of genetic associations was *B. wexlerae*.  
240 The inter-individual genetic differences of *B. wexlerae* were significantly associated  
241 with 27 BA parameters (PERMANOVA,  $\text{FDR}_{\text{Meta}} < 0.05$ ; **Table S6**), whereas only 6  
242 BA parameters correlated with the relative abundance of *B. wexlerae* (Linear  
243 regression,  $\text{FDR}_{\text{Meta}} < 0.05$ ; **Table S6**). The strongest genetic association of *B.*

244 *wexlerae* was with plasma CA proportion ( $P_{\text{Meta}} = 8.70 \times 10^{-6}$ ; **Figure 3B; Table S6**),  
245 indicating that individuals with very similar *B. wexlerae* genome content tend to have  
246 similar CA-contributions to their plasma BA content. Another species, *F. prausnitzii*,  
247 contributes to 12-dehydro-CA production, and the depletion of *F. prausnitzii* was  
248 inferred to lower the unconjugated CA and CDCA levels in feces of IBD patients  
249 (Heinken et al., 2019). In addition to associations at species-abundance level, genetic  
250 differences in *F. prausnitzii* were also associated with 23 BA parameters (**Table S6**).  
251 For instance, genetic differences in *F. prausnitzii* correlated with the proportion of  
252 GUDCA in plasma (PERMANOVA,  $\text{FDR}_{\text{Meta}} < 0.05$ ; **Figure 3C; Table S6**), even  
253 though the association was not significant at species-abundance level. Altogether, we  
254 observed that species-specific genetic makeup is highly variable and correlates with  
255 BA composition independent of the relative abundances of the species in the  
256 microbial community.  
257

#### 258 **Discrete subspecies correlate with human BA metabolism**

259 Based on the genetic differences between species, we stratified the population genetic  
260 structure for each species using the partitioning around medoid-based method  
261 (**STAR-Method; Figure S4**) and detected two or more subspecies for 29 of the 55  
262 species (**Figures S5 and S6; Table S7**). Some subspecies have been previously  
263 reported based on different methods. For instance, we identified two *E. rectale*  
264 subspecies and four *A. muciniphila* subspecies in our cohorts, while Costea *et al.*  
265 observed three *E. rectale* and two *A. muciniphila* subspecies based on a single-  
266 nucleotide variant (SNV)-typing profile in 2,144 samples (Costea et al., 2017). All the  
267 subspecies we identified could be detected in both LLD and 300-OB samples, but the  
268 subspecies proportions of *P. copri*, *S. vestibularis* and *P. merdae* showed different  
269 enrichments in LLD and 300-OB (chi-square test,  $\text{FDR} < 0.05$ ). Of these, *P. copri*  
270 subspecies 1, *S. vestibularis* subspecies 1 and *P. merdae* subspecies 2 were enriched  
271 in LLD, whereas *P. copri* subspecies 2, *S. vestibularis* subspecies 3 and *P. merdae*  
272 subspecies 1 were enriched in 300-OB (Chi-square test,  $\text{FDR} < 0.05$ ; **Figure S7;**  
273 **Table S8**). Consistent with the previous results reported for SNV-based subspecies of  
274 *E. rectale* (Costea et al., 2017), the SV-based subspecies of *E. rectale* we identified  
275 was also associated with host BMI (Wilcoxon test,  $P = 0.0045$ ).

276 The presence of different subspecies may differentially affect BA metabolism.  
277 We therefore conducted an association analysis between the SV-based subspecies and  
278 plasma BA parameters and found 41 significant associations (Permutational Kruskal-  
279 Wallis rank-sum test, FDR < 0.05; **Figure 4; Table S9**). *E. rectale* showed the highest  
280 number of associations with BAs (10 associations), followed by *R. gnavus* (8  
281 associations). The most significant association was between *E. rectale* and C4  
282 concentration (Permutational Kruskal-Wallis rank-sum test, FDR =  $2.26 \times 10^{-5}$ ). We  
283 compared the SV profiles of two subspecies of *E. rectale* and found that 55 of the 56  
284 vSVs and 72 of the 124 dSVs were significantly enriched in subspecies 1 or 2  
285 (Wilcoxon test for vSV and Chi-square test for dSV, FDR < 0.05). Although no  
286 enrichment was observed for BA biotransformation genes between *E. rectale*  
287 subspecies, their wide association with BA parameters may reflect a physiological  
288 impact of bacterial subspecies diversity on BA metabolism, or *vice versa*. The  
289 antimicrobial activity of BAs exerts survival pressure on microbes (Langdon et al.,  
290 2016; Tian et al., 2020), which may drive some or all of the changes in bacterial  
291 genomes.

292

### 293 **Metagenome-wide SV-based association identifies BA-associated microbial** 294 **genomic segments**

295 To identify SVs that potentially harbor genes involved in human BA metabolism, we  
296 performed a metagenome-wide microbial SV-based association study on the BA  
297 parameters. Considering the significant differences in plasma BA composition and  
298 microbial genetic makeup between LLD and 300-OB, we associated the 8,282 SVs  
299 with the 39 plasma BA parameters using linear models for LLD and 300-OB  
300 respectively, followed by meta- and heterogeneity analysis (random effect model). In  
301 addition to age, sex, BMI and total read counts, we also included the corresponding  
302 species abundances as a covariate because we observed that the abundance levels of  
303 34 of the 55 species were associated with at least one BA parameter (**Table S6**). In  
304 total, we identified 792 significant and replicable associations in our meta-analysis  
305 using a random effect model ( $FDR_{meta} < 0.05$ ), including 725 associations with vSVs  
306 (**Figure S8A; Table S10**) and 67 associations with dSVs (**Figure S8B; Table S11**).  
307 The effect sizes and directions of all 792 associations were highly consistent between

308 cohorts ( $P_{\text{hetero}} < 0.05$ ; **Figure S8C and S8D**). These results indicate that the SV  
309 associations we identified were robust and replicable between the two cohorts despite  
310 the large differences in their profiles of gut microbial genetic makeup and plasma BA  
311 composition.

312 The 792 replicable SV-BA associations linked 300 SVs of 33 species with 32  
313 plasma BA parameters (**Figure 5A**), indicating that BA-related SVs are highly  
314 prevalent across gut bacterial species. 183 (23.11%) of the 792 replicable associations  
315 were for *B. wexlerae* (**Figure 5B**). In the genome of *B. wexlerae*, 52 SVs were  
316 associated with 21 BA parameters ( $FDR_{\text{Meta}} < 0.05$ ; **Figure 5B**), with the most  
317 significant association being between the variable SV region 1715-1716 kbp and the  
318 CA dehydroxylation/deconjugation ratio ( $\text{Beta} = -0.29$ ,  $P_{\text{meta}} = 2.18 \times 10^{-23}$ ; **Table S10**).  
319 Since the reference genome of *B. wexlerae* was not well annotated in the database  
320 provided by SGVFinder, we further annotated its genome with PATRIC  
321 (**STAR Methods**) and identified three genes that encode choloylglycine hydrolase  
322 (or bacterial BSH; EC number: EC 3.5.1.24), which catalyzes the deconjugation of  
323 glycine- and taurine-conjugated BAs. One of the annotated BSH genes is located in  
324 the region of 2,938,104–2,938,946 bp, which is close to three BA-associated SVs of *B.*  
325 *wexlerae* that span four genomic segments (2,079–2,081 kbp, 2,081–2,082 kbp,  
326 2,083–2,084, and 2,086–2,090 kbp) (**Figure 5B and 5C**). These three SVs also  
327 significantly correlated with 10 BA parameters ( $FDR_{\text{Meta}} < 0.05$ ; **Figure 5B**), and the  
328 most significant association was with DCA concentration ( $\text{Beta}_{\text{Meta}} = -0.23$ ,  $P_{\text{Meta}} =$   
329  $1.67 \times 10^{-16}$ ; **Figure 5D; Table S10**). This is in line with recent findings that fecal  
330 CDCA and CA were associated with several SVs of *B. wexlerae* (Mars et al., 2020).  
331 Our study further confirms that *B. wexlerae* is a novel bacterium involved in BA  
332 transformation that possesses BA metabolism-related genes.

333 Besides *B. wexlerae*, we also identified BA biotransformation genes near the  
334 associated SV regions in several other species. For instance, a 5-kbp vSV  
335 (2,932–2,935 and 2,935–2,937 kbp) of *Coprococcus comes* harbors a BSH gene  
336 (2,938,104–2,938,946 bp) that was significantly associated with 12 BA parameters  
337 (**Figure 5E; Table S10**), of which the strongest association was with the  
338 secondary/primary BA ratio ( $\text{Beta}_{\text{Meta}} = 0.36$ ,  $P_{\text{Meta}} = 4.77 \times 10^{-34}$ ; **Figure 5F**). This  
339 appeared to be the most significant association among all SV-BA associations. In  
340 addition to being found in the most prevalent species, BA biotransformation genes

341 were also found in some low prevalence species. For instance, near a BSH gene  
342 (genomic position: 1,519,343–1,520,332 bp) in the genome of *E. ventriosum*, three  
343 variable SVs were significantly associated with 10 BA parameters ( $FDR_{Meta} < 0.05$ )  
344 (**Figure 5G; Table S10**), of which the most significant association was between the  
345 vSV region 1,512–1,517 kbp and the secondary/primary BA ratio ( $Beta_{Meta} = -0.41$ ;  
346  $P_{Meta} = 1.06 \times 10^{-7}$ ; **Figure 5H**).

347 We also identified 118 BA–SV associations with significant heterogeneity  
348 between our general population- and obesity-based cohorts ( $P_{hetero} < 0.05$ ,  $FDR_{LLD} <$   
349  $0.05$  and/or  $FDR_{300-OB} < 0.05$ ; **Table S12 and S13**). The most significant  
350 heterogeneity was observed for the association between a 3-kbp vSV of *Escherichia*  
351 *coli* (1,062–1,065 kbp) and TCDCA proportion ( $Beta_{LLD} = -0.16$ ,  $FDR_{LLD} = 0.76$ ,  
352  $Beta_{300-OB} = 0.68$ ,  $FDR_{300-OB} = 0.032$ ,  $P_{hetero} = 3.24 \times 10^{-6}$ ; **Table S12**). This variable  
353 genomic region contains two genes, *Salmocheilin siderophore protein IroE* and  
354 *Enterochelin esterase*, that play a role in maintaining iron homeostasis of *E. coli*. A 1-  
355 kbp vSV of *C. comes* (966–967 kbp) harboring a BSH gene was associated with three  
356 BA parameters (CA/CDCA ratio, secondary/primary BA ratio and DCA proportion)  
357 with significant heterogeneity between LLD and 300-OB ( $P_{hetero} < 0.05$ ; **Table S12**),  
358 and the effect sizes of the BA associations were higher in 300-OB than in LLD.  
359

## 360 **Bi-directional causality between bacterial SVs and host BAs**

361 The genetic makeup of gut bacteria can be affected by host-specific features and  
362 environmental factors, thus a symbiotic genomic variant–based GWAS alone will not  
363 be sufficient to provide causal interpretation of the relationships between correlated  
364 microbial variants and host phenotypes. Although we did identify several bacterial  
365 genes known to be involved in BA biotransformation that were located in BA-  
366 associated SV regions, the causality behind most of the BA–SV associations we  
367 identified remains unknown. The lifestyle exposure factors collected in the LLD  
368 cohort enabled us to infer *in silico* causal relationships between correlated SVs and  
369 BAs and identify lifestyle factors that may impact the interactions between gut  
370 microbial genetics and host BA metabolism. We integrated 127 lifestyle factors (78  
371 dietary factors, 44 drug usage factors and 5 smoking-related factors; **Table S14**) with  
372 SV and BA data. Here, we first identified lifestyle–SV–BA groups in which all the

373 variables correlated with each other and then conducted bidirectional mediation  
374 analysis. In the first causal direction, we hypothesized that SVs act as regulators that  
375 mediate the effects of lifestyle factors on the composition of the BA pool and thus  
376 treated SVs as mediators and BA parameters as outcomes. In the second causal  
377 direction, we assessed whether BAs can mediate the effects of lifestyle factors on  
378 bacterial SVs (**Figure 6A**). In total, we identified 502 groups of inferred *in silico*  
379 causal relationships, including 38 unidirectional causal relationships in direction 1,  
380 216 unidirectional causal relationships in direction 2 and 248 bidirectional causal  
381 relationships (**Figure 6B**,  $FDR_{\text{mediation}} < 0.05$ ).

382 The tripartite causal network in direction 1 was composed of 18 lifestyle factors,  
383 32 SVs as mediators and 17 plasma BA parameters as outcomes ( $FDR_{\text{mediation}} < 0.05$ ,  
384 **Figure 6C**, **Table S15**). Notably, 15 of the 32 SVs were from *B. wexlerae*, including  
385 the SVs with known BA biotransformation genes. For instance, a 2-kbp vSV  
386 (2079–2081 kbp) close to a BSH gene in *B. wexlerae* regulated the effect of drinking  
387 red wine on the CA dehydroxylation/deconjugation ratio ( $FDR_{\text{mediation}} < 0.05$ ;  
388 Mediated proportion = 33%; **Figure 6D**). Another SV of *B. wexlerae* in 3513–3516  
389 kbp mediated both the positive effect of the frequency chocolate consumption on  
390 GUDCA proportion in plasma ( $FDR_{\text{mediation}} < 0.05$ ; Mediated proportion = 13%;  
391 **Figure 6E**) and the inverse effect of smoking habit on this parameter ( $FDR_{\text{mediation}} <$   
392  $0.05$ ; Mediated proportion = 18%; **Figure 6F**). These findings indicate that gut  
393 bacterial genes involved in BA metabolism can be regulated by lifestyle factors and  
394 thereby affect the composition of the host's BA pool. The inferred regulatory SVs that  
395 causally affect the composition of host BA pool may contain novel genes involved in  
396 BA biosynthesis and biotransformation and can potentially be used as targets to  
397 regulate BA metabolism.

398 We found 216 *in silico* causal relationships in which 22 BA parameters mediated  
399 the effects of 43 lifestyle factors on 80 bacterial SVs belonging to 12 bacterial species  
400 ( $FDR_{\text{mediation}} < 0.05$ ; **Table S15**). Among the 80 regulated SVs, 29 were from *B.*  
401 *wexlerae*, followed by 11 from *R. torques*. In mice, the growth of *Ruminococcus*  
402 species can be inhibited by DCA (Tian et al., 2020), and we found 8 SVs of  
403 *Ruminococcus* species to be negatively regulated by both DCA concentration and  
404 proportion ( $FDR_{\text{mediation}} < 0.05$ ), indicating that enrichment of the circulating BA pool  
405 with DCA may exert selective pressure on *Ruminococcus* species and cause a loss of

406 their genomic content.

407

## 408 **Discussion**

409 We characterized the gut microbial SV and plasma BA profiles of 1,437 Dutch  
410 individuals from two independent cohorts and systemically assessed the correlation  
411 between gut microbial genetics and host BA metabolism from species genetic makeup  
412 level down to single variant level. Species genetic makeup was found to correlate with  
413 BA parameters independent of the relative abundances of these species. We also  
414 identified subspecies of 29 bacterial species using SV-based clustering analysis,  
415 revealed the within-species genetic differentiation and diversity and associated the  
416 SV-based subspecies with plasma BA parameters. We further performed a  
417 metagenome-wide microbial SV association study on 39 BA parameters and  
418 identified 786 replicable associations between SVs and BA parameters and 118  
419 heterogeneous associations using meta-analysis. Bi-directional mediation analysis  
420 inferred *in silico* regulatory relationships behind the correlations we identified. Our  
421 study thus provides a resource of bacterial genomic entities that potentially contain  
422 novel genes involved in human BA metabolism while also revealing genetic shifts in  
423 the bacterial genomes that are potentially due to the antimicrobial effects of specific  
424 BAs within the intestinal lumen. To the best of our knowledge, this is the largest  
425 study so far on microbial genetic determinants of plasma BA concentrations and  
426 composition in humans. In view of the growing awareness of the involvement of  
427 specific BAs in the onset and progression of human diseases (Chávez-Talavera et al.,  
428 2017; Dermadi et al., 2017; Gao et al., 2019), as well as the current development of  
429 pharmacological agents that target BA-signaling pathways for treatment of liver and  
430 metabolic diseases (Jia et al., 2017; Krautkramer et al., 2021; Pathak et al., 2018; Sun  
431 et al., 2018), this knowledge is of direct clinical relevance.

432 Our study demonstrates that SV-based metagenome-wide association is a  
433 powerful method to bring microbial associations closer to functionality and  
434 mechanistic understanding. Firstly, our study shows that the BA associations with  
435 microbial SVs were often stronger than those with species relative abundances and  
436 can even be independent of species relative abundances. This highlights the value of  
437 metagenomic SVs as a new source of information that describes the functionality of  
438 the human gut microbiome. Although previous studies identified some BA-  
439 metabolizing species (Krautkramer et al., 2021; Li et al., 2021), our metagenome-  
440 wide SV association study supplements the list of novel bacterial species that interact

441 with BA metabolism, adding *Blautia wexlerae*, *Eubacterium rectale*, *Blautia obeum*  
442 and *Ruminococcus torques*, amongst others. The sub-genome scale analysis also  
443 pinpoints the location of genomic segments that associate with host BA pool, which  
444 means that association of microbial SV across the whole metagenome with host  
445 phenotypes helps to locate microbial genes or genetic elements involved in  
446 host-microbe interaction. Our study underscores the contribution of gut microbial  
447 genetics to the individuality of host BA metabolism. The comprehensive association  
448 analysis approach we used provides a template for cohort-based microbial genetics  
449 studies, demonstrating a paradigm shift from “micro-ecology” to “micro-population  
450 genetics”.

451 Our study further highlights the complex, bi-directional effect between the gut  
452 microbiome and BA metabolism. We used lifestyle factors as exogenous predictors to  
453 infer *in silico* potential causal relationships between SVs and BAs using bidirectional  
454 mediation analysis and identified specific lifestyle factors involved in the interaction  
455 between bacterial genetics and BA metabolism. This highlights the potential of  
456 targeting the gut microbiota to regulate BA metabolism through lifestyle intervention.  
457 For instance, we found that an SV of *B. wexlerae* mediated the effect of red wine  
458 drinking on the CA dehydroxylation/deconjugation ratio, reflecting the conversion of  
459 glycine- or taurine-conjugated CA to unconjugated DCA within one cycle of the  
460 enterohepatic circulation. Red wine is rich in polyphenols, a group of molecules with  
461 anti-oxidative properties (Naumann et al., 2020; Queipo-Ortuño et al., 2012) that can  
462 increase fecal BA excretion by regulating gut microbiota (Chambers et al., 2019). We  
463 also observed that the frequency of chocolate consumption increases the GUDCA  
464 proportion in plasma through an SV of *B. wexlerae*. GUDCA is a hydrophilic BA that  
465 has been suggested to act as an antagonist of human FXR and to contribute to the  
466 beneficial effects of metformin in subjects with T2D (Sun et al., 2018). Furthermore,  
467 its parent molecule, UDCA, is widely used in treatment of cholestatic liver diseases  
468 and has been suggested as a potential drug for the treatment of T2D and other  
469 metabolic diseases (Pathak et al., 2018; Sun et al., 2018). Chocolate is rich in  
470 flavonoids, a subclass of polyphenols. Thus, it appears that polyphenols from  
471 chocolate increase the level of GUDCA by regulating gut bacterial genes. Previous  
472 studies reported that dietary polyphenols from plant-derived foods can affect the  
473 composition of fecal BAs in humans by regulating gut microbiota (Chambers et al.,

474 2019; Ozdal et al., 2016; Queipo-Ortuño et al., 2012; Sembries et al., 2006). Our *in*  
475 *silico* causal inference analysis revealed that the bacterial SV serves as a mediator that  
476 regulates the effects of dietary polyphenols on BA metabolism. Conversely, our study  
477 also provided evidence that BAs, likely via their anti-bacterial activities as “intestinal  
478 soaps”, not only affect the growth of intestinal microbes but also pose selective  
479 pressure on bacterial genetics.

#### 480 **Limitations of the study**

481 We acknowledge several limitations of our current study. We investigated the  
482 association between plasma BA parameters and variable genomic segments of gut  
483 bacteria in two independent cohorts, identified substantial consistent associations in  
484 both these general population and obese individuals, and demonstrated the reliability  
485 of BA associations with microbial SVs. However, all the samples included in this  
486 study were collected from the residents of the Netherlands. Considering the potential  
487 heterogeneity of host-microbiome interaction across populations with different  
488 genetic and environmental backgrounds, the associations between plasma BA  
489 parameters and microbial SVs need to be replicated in other populations with different  
490 background. As this is a cross-sectional study, we inferred the regulatory relationships  
491 between BA parameters and microbial SVs using mediation analysis, but whether the  
492 shifts of microbial genetic elements causally correlate with host BA metabolism still  
493 requires further confirmation in a longitudinal study design and through experimental  
494 validation. Additionally, plasma BA parameters cannot fully represent the flux of the  
495 BA pool in enterohepatic circulation and are only modestly correlated with the fecal  
496 BA pool (Chen et al., 2020), further study of the association between microbial  
497 genetic variation and BA metabolism in their actual niche – the enterohepatic  
498 circulation – is thus needed. Despite these limitations, our study represents a step  
499 towards successful microbiome-targeted interventions to improve host metabolism, in  
500 particular through modulation of BA metabolism, which is a major target for the  
501 treatment of NAFLD and its metabolic co-morbidities.

502

503

504 **Supplemental information**

505 Supplemental materials are available.

506

507 **Acknowledgements**

508 We thank all the volunteers in the LifeLines-DEEP cohort and 300-Obesity cohort of  
509 the Human Functional Genomics Project (HFGP) for their participation and the  
510 project staff for their help and management. This study was supported by an IN-  
511 CONTROL CVON grant (CVON2012-03, CVON2018-27) to N.P.R., M.G.N., A.Z.,  
512 F.K. and J.F. J.F. is supported by an ERC Consolidator grant (101001678) and the  
513 Netherlands Organ-on-Chip Initiative, an NWO Gravitation project (024.003.001)  
514 funded by the Ministry of Education, Culture and Science of the government of the  
515 Netherlands. F.K. is supported by the Noaber Foundation, Lunteren, the Netherlands.  
516 A.Z. is supported by ERC Starting Grant 715772, NWO-VIDI grant 016.178.056 and  
517 NWO Gravitation grant Exposome-NL (024.004.017). D.W. is supported by China  
518 Scholarship Council (CSC201904910478). L.C. holds a joint fellowship from the  
519 University Medical Centre Groningen and China Scholarship Council  
520 (CSC201708320268) and a Foundation de Cock-Hadders grant (20:20-13). M.D.  
521 holds a MD-PhD fellowship from the University Medical Center Groningen. We also  
522 thank the Genomics Coordination Center for providing data infrastructure and access  
523 to high performance computing clusters and Kate McIntyre for critical reading and  
524 editing.

525

526 **Author contributions**

527 J.F., F.K. and A.Z. conceptualized and managed the study. D.W., M.D., L.C.,  
528 I.C.L.v.d.M., M.K., N.P.R. and J.H.W.R. contributed to sample collection and data  
529 generation. D.W. analyzed the data. D.W., J.F. and F.K. drafted the manuscript. D.W.,  
530 M.D., L.C., S.A.S., I.C.L.v.d.M., H.A., M.K., V.W.B., N.P.R., J.H.W.R., M.G.N.,  
531 A.Z., F.J. and F.K. reviewed and edited the manuscript.

532

533 **Competing interests**

534 The authors declare no competing interests.

535

536 **Additional information**

537 **Lead contact**

538 Further information and requests for resources, software, reagents and data sharing  
539 should be directed to the Lead Contact, Jingyuan Fu ([j.fu@umcg.nl](mailto:j.fu@umcg.nl)).

540 **Data and Code Availability**

541 Raw metagenomic sequencing data of LifeLines-DEEP and 300-Obesity are publicly  
542 available at European Genome-Phenome Archive via accession numbers  
543 EGAS00001001704 and EGAS00001003508, respectively. The code used for the  
544 statistical analysis is available via [https://github.com/GRONINGEN-MICROBIOME-](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/SV_BA)  
545 [CENTRE/Groningen-Microbiome/tree/master/Projects/SV\\_BA](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/SV_BA).

546

547

548 **Figure legends**

549 **Figure 1. High variability in human fasting plasma bile acid concentration and**  
550 **composition. A.** Sex proportions of LLD and 300-OB. **B.** Age distribution in LLD  
551 and 300-OB. **C.** BMI distribution in LLD and 300-OB. **D.** Concentrations of 15 bile  
552 acids (BAs) in fasting plasma across all samples of LLD and 300-OB. **E.** Proportions  
553 of 15 BAs in plasma across all samples of LLD and 300-OB. Samples were sorted by  
554 the proportion of the primary BAs (cholic and chenodeoxycholic acid and their  
555 conjugated forms) within each cohort. The order of samples is identical in **(D)** and **(E)**.  
556 **F-E,** Principal coordinates analysis (PCoA) plot of the differences between all  
557 samples based on BA concentration profile **(F)** and BA proportion profile **(E)**. **H-I,**  
558 Explained variance proportions ( $R^2$ ) of BA concentration **(H)** and proportion **(I)**  
559 profiles by sex, age and BMI. Blue bars indicate the cumulative explained BA  
560 variance proportion in multivariate models. Green bars indicate individually explained  
561 BA variance proportion by each factor in univariate models.

562

563 **Figure 2. Overview of structural variation profile in LLD and 300-OB. A.**  
564 Number of structural variants (SV) of each species. **B.** Total SV numbers. **C.**  
565 Population structure of SV-based genetic makeup.

566

567 **Figure 3. Species-level associations of gut microbiome with human bile acid**  
568 **parameters. A.** Heatmap of species-level associations with BA parameters. Blue  
569 indicates purely genetics-based associations. Yellow indicates purely relative  
570 abundance-based associations. Red indicates associations based on both genetics and  
571 relative abundance. Black indicates genetics-based associations where relative  
572 abundance is not available for the corresponding species. White indicates no  
573 association. **B.** Genetic association of *B. wexlerae* with CA proportion in plasma, the  
574 color scale from red to blue represents the increase in standardized value of CA  
575 proportion. **C.** Genetic association of *F. prausnitzii* with GUDCA proportion in  
576 plasma the color scale from red to blue represents the increase in standardized value  
577 of GUDCA proportion.

578

579 **Figure 4. Bile acid parameters correlate with structural variant-based**  
580 **subspecies.** The subspecies of 13 species are shown by the t-SNE plots, with distinct

581 subspecies shown by different colors. The circos correlation plot shows their  
582 associations with BA. Each line indicates an association between subspecies of a  
583 species and plasma levels of a BA parameter.

584

585 **Figure 5. Associations between bile acid parameters and structural variants. A.**

586 Replicable significant associations between BA parameters and SVs ( $FDR_{Meta} < 0.05$ ).

587 **B.** Heatmap of associations between BA parameters and SVs of *Blautia wexlerae*. **C-**

588 **H.** Examples of SV regions close to known BA biotransformation genes (**C, E, and G**)

589 and associations with BA parameters (**D, F, and H**). Blue and yellow circles represent

590 LLD and 300-OB samples, respectively.

591

592 **Figure 6. Causal relationship inference using bi-directional mediation analysis. A.**

593 Framework of bi-directional mediation analysis between lifestyle factors, SVs and

594 BAs. **B.** Number of inferred causal relationships for direction 1 (from SV to BA),

595 direction 2 (from BA to SV), and both. **C.** Sankey diagram showing the inferred

596 causal relationship network of direction 1. **D-F.** Examples of causal relationships

597 between lifestyle factors, SVs and BAs inferred by bi-directional mediation analysis.

598 The beta coefficient and significance are labeled at each edge and the proportions of

599 indirect effect (mediation effect) are labeled at the center of the ring charts.

600

601

602 STAR Methods

603 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Biological Samples</b>		
Fecal samples	This study	
Blood samples	This study	
<b>Critical Commercial Assays</b>		
AllPrep DNA/RNA Mini Kit	QIAGEN	80204
Quant-iT PicoGreen dsDNA Assay	Life Technologies	P7589
Bile Acid Assays	(Hoogerland et al., 2019)	PMID: 31102537
Blood Assays	Lifelines Biobank	<a href="https://www.lifelines.nl">https://www.lifelines.nl</a>
<b>Deposited Data</b>		
Metagenomic sequencing data of LifeLines-DEEP	This study	European Genomics-Phenome Archive, EGAS00001001704
Metagenomic sequencing data of 300-Obesity	This study	European Genomics-Phenome Archive, EGAS00001003508
<b>Software and Algorithms</b>		
Bowtie2 (version 2.3.4.3)	(Langmead and Salzberg, 2012)	<a href="http://bowtie-bio.sourceforge.net/bowtie2/index.shtml">http://bowtie-bio.sourceforge.net/bowtie2/index.shtml</a>
Trimmomatic (version 0.39)	(Bolger et al., 2014)	<a href="http://www.usadellab.org/cms/?page=trimmomatic">http://www.usadellab.org/cms/?page=trimmomatic</a>
KneadData (version 0.7.4)	Huttenhower lab	<a href="https://huttenhower.sph.harvard.edu/kneaddata/">https://huttenhower.sph.harvard.edu/kneaddata/</a>
MetaPhlan3	(Beghini et al., 2020)	<a href="https://huttenhower.sph.harvard.edu/metaphlan3/">https://huttenhower.sph.harvard.edu/metaphlan3/</a>
ICRA	(Zeevi et al., 2019)	<a href="https://github.com/segalab/SGVFinder">https://github.com/segalab/SGVFinder</a>
SGVFinder	(Zeevi et al., 2019)	<a href="https://github.com/segalab/SGVFinder">https://github.com/segalab/SGVFinder</a>
R (version 4.0.1)	R Core Team	<a href="https://www.r-">https://www.r-</a>

		<a href="https://www.python.org/">project.org/</a>
Python (version 2.7.16)	Python Core Team	<a href="https://www.python.org/">https://www.python.org/</a>
PATRIC (version 3.6.6)	(Wattam et al., 2017)	<a href="https://www.patricbrc.org/">https://www.patricbrc.org/</a>
Other		
Progenome	(Mende et al., 2017)	<a href="http://progenomes1.embl.de/">http://progenomes1.embl.de/</a>

604

## 605 **RESOURCE AVAILABILITY**

### 606 **Lead Contact**

607 Further information and requests for resources, software, reagents and data sharing  
608 should be directed to the Lead Contact, Jingyuan Fu ([j.fu@umcg.nl](mailto:j.fu@umcg.nl)).

### 609 **Materials Availability**

610 This study did not generate new unique reagents.

### 611 **Data and Code Availability**

612 Raw metagenomic sequencing data of LifeLines-DEEP and 300-Obesity are publicly  
613 available from the European Genome-Phenome Archive via accession number  
614 EGAS00001001704 and EGAS00001003508, respectively. The code used for  
615 statistical analysis is available via [https://github.com/GRONINGEN-MICROBIOME-](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/SV_BA)  
616 [CENTRE/Groningen-Microbiome/tree/master/Projects/SV\\_BA](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/SV_BA) .

617

## 618 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

### 619 **LifeLines-DEEP cohort**

620 LifeLines-DEEP (LLD) is a sub-cohort of LifeLines, a large population-based  
621 prospective cohort that enrolled 167,729 participants from the north of Netherlands,  
622 established to explore the risk factors of complex diseases. In LLD, 1,539 individuals  
623 were included and multi-layers of omics data were collected. In the current study,  
624 high-quality metagenomic sequencing data, 78 dietary factors, 5 smoking factors and  
625 44 drug usage factors were available for 1,135 individuals (474 males and 661  
626 females). The average age of LLD participants was 45.04 years old (18–81, SE =  
627 0.40) and the average BMI was 25.26 (16.67–48.56, SE = 0.12).

628 **300-Obesity cohort**

629 The 300-Obesity (300-OB) cohort was established by Radboud University Medical  
630 Center, Nijmegen, the Netherlands (Horst et al., 2019). In total, 302 individuals (167  
631 males and 135 females) aged 55–81 years with a high body mass index (BMI) > 27  
632 were enrolled in 300-OB. The average age of 300-OB participants was 67.1 years old  
633 (54–81, SE = 0.31) and the average BMI was 30.7 (26.3–45.5, SE = 0.20). All  
634 participants were included between 2014 and 2016.

635 **Ethical approval**

636 The LifeLines-DEEP study has been approved by the Institutional ethics Review  
637 Board (IRB) of the University Medical Center Groningen (ref. M12.113965), the  
638 Netherlands. The 300-Obesity study has been approved by the IRB CMO Regio  
639 Arnhem-Nijmegen (nr. 46846.091.13).

640

641 **METHOD DETAILS**

642 **Bile acid quantification**

643 Levels of 15 BAs and C4 concentrations in fasting plasma were quantified by liquid  
644 chromatography–mass spectrometry (LC-MS) procedures, as previously described  
645 (Eggink et al., 2017; Hoogerland et al., 2019). The proportions of 15 BAs (with suffix  
646 ‘\_p’) were calculated by dividing by total BA concentration. Additionally, 8 indices  
647 of BA metabolism were calculated (Chen et al., 2020): (1) Total BA (Total\_BAs) =  
648 sum of all BA concentrations, (2) total primary BA (Total\_primary\_BAs) = sum of all  
649 primary BA concentrations, (3) total secondary BA (Total\_secondary\_BAs) = sum up  
650 of all secondary BA concentrations, (4) ratio of Secondary BAs to primary BAs ratio  
651 (Secondary\_primary\_ratio) = Total\_primary\_BAs/Total\_secondary\_BAs, (5) ratio of  
652 CA to CDCA concentrations (CA\_CDCA\_ratio) = (CA + TCA + GCA)/(CDCA +  
653 TCDCA + GCDCA), (6) ratio of unconjugated BA to conjugated BA concentrations =  
654 (CA + CDCA + DCA + LCA)/(TCA + GCA + TCDCA + GCDCA + TDCA +  
655 GDCA + TLCA + GLCA), (7) ratio of dehydroxylated CA to deconjugated CA  
656 concentrations (CA\_dehydro\_deconju\_ratio) = (DCA + TDCA + GDCA)/(CA + TCA  
657 + GCA) and (8) ratio of taurine conjugated BA to glycine conjugated BA  
658 concentrations (Taurine\_glycine\_ratio) = (TCA + TCDCA + TDCA + TLCA)/(GCA  
659 + GCDCA + GDCA + GLCA).

## 660 **Metagenomic sequencing and quality control**

661 Microbial DNA was isolated from fecal samples of LLD and 300-OB and sequenced  
662 as previously described (Kurilshikov et al., 2019; Zhernakova et al., 2016). We  
663 removed host genome-contaminated reads and low-quality reads from the raw  
664 metagenomic sequencing data using KneadData (version 0.7.4), Bowtie2 (version  
665 2.3.4.3) (Langmead and Salzberg, 2012) and Trimmomatic (version 0.39) (Bolger et  
666 al., 2014). In brief, the data-cleaning procedure includes two main steps: (1) filtering  
667 out the human genome-contaminated reads by aligning raw reads to the human  
668 reference genome (GRCh37/hg19) and (2) removing adaptor sequences and low-  
669 quality reads using Trimmomatic with default settings (SLIDINGWINDOW:4:20  
670 MINLEN:50).

## 671 **Taxonomic abundance**

672 We generated the taxonomic relative abundance for both LLD and 300-OB samples  
673 from the cleaned metagenomic reads using MetaPhlan3 with default parameters  
674 (Beghini et al., 2020).

## 675 **Detection of structural variations**

676 Structural variants (SVs) are highly variable genomic segments within bacterial  
677 genomes that can be absent from the metagenomes of some individuals and present  
678 with variable abundance in other individuals. Based on the cleaned metagenomic  
679 reads, we detected the microbial SVs of all 1,437 samples from LLD and 300-OB  
680 using SGVFinder with default parameters. SGVFinder was devised and described by  
681 (Zeevi et al., 2019) and can detect two types of SV – deletion SVs (dSVs) and  
682 variable SVs (vSVs) – from metagenomic data. If the deletion percentage of the  
683 genomic segment across the population is < 25%, the standardized coverage will be  
684 calculated for this SV (vSV). If the deletion percentage is > 25% and < 75%, only the  
685 presence or absence status of this genomic segment will be kept (dSV). If the deletion  
686 percentage of a region is > 75%, the region is excluded from the analysis. The SV-  
687 calling procedure includes two major steps: (1) resolving ambiguous reads with  
688 multiple alignments according to the mapping quality and genomic coverage using the  
689 iterative coverage-based read assignment algorithm and reassigning the ambiguous  
690 reads to the most likely reference with high accuracy and (2) splitting the reference  
691 genomes into genomic bins and then examining the coverage of genomic bins across  
692 all samples to identify highly variable genomic segments and detect SVs. We used the

693 reference database provided by SGVFinder, which is based on the proGenomes  
694 database (<http://progenomes1.embl.de/>) (Mende et al., 2017). In total, we detected  
695 5,666 dSVs and 2,616 vSVs from 55 bacteria using default parameters. All bacterial  
696 species with SV calling were present in at least 5% of total samples.

#### 697 **Functional annotation**

698 The reference genome of *Blautia wexlerae* DSM 19850, *Coprococcus comes* ATCC  
699 27758, *Eubacterium ventriosum* ATCC 27560, *Eubacterium hallii* DSM 3353 and  
700 *Eubacterium rectale* DSM 17629 were downloaded from progenome  
701 (<http://progenomes1.embl.de/>) (Mende et al., 2017) and annotated using the web-  
702 based genome annotation service provided by PATRIC (version 3.6.6,  
703 <https://www.patricbrc.org/>) (Wattam et al., 2017).

704

#### 705 **QUANTIFICATION AND STATISTICAL ANALYSIS**

706 All statistical tests were performed using R (version 4.0.1). Details of statistical tests  
707 are also provided in results and figure legends.

#### 708 **Association analysis**

709 Before association analysis, all continuous variables were standardized to follow a  
710 standard normal distribution ( $N \sim (0, 1)$ ) using empirical normal quantile  
711 transformation. Associations between SV and BAs were assessed in LLD and 300-OB  
712 using linear models with the following formula:

713 
$$BA \sim SV + Age + Sex + BMI + Reads\ number + Species\ relative\ abundance$$

714 The association between species relative abundance and BA parameters were  
715 assessed in LLD and 300-OB using linear model with following formula:

716 
$$BA \sim Species\ relative\ abundance + Age + Sex + BMI + Reads\ number$$

717 The association results of LLD and 300-OB were furtherly integrated using meta-  
718 analysis with a random-effect model, while the statistical heterogeneities were  
719 estimated with  $I^2$ . To control the false discovery rate (FDR), Benjamina-Hochberg  
720 and Bonferroni P-value correction were performed using  $p.adjust()$  function in R. The  
721 association analysis and P-value correction were conducted for vSVs, dSVs and  
722 species relative abundance separately. The replicable significant SV  $\square$  BA associations

723 were confirmed with following four criteria: (1)  $P_{LLD} < 0.05$ , (2)  $P_{300-OB} < 0.05$ , (3)  
724  $FDR_{meta} < 0.05$  and (4)  $P_{heterogeneity} > 0.05$ .

725 The differences of BA parameters between SV-based clusters within species were  
726 tested using the Kruskal-Wallis rank-sum test. Empiric P values were estimated based  
727 on 999 permutations. For the analysis shown in **Figures S8C** and **S8D**, the Spearman  
728 correlation coefficient was calculated between the effect size in LLD and 300-OB. In  
729 **Figure S1A**, the mean value  $\pm$  standard deviation is shown.

### 730 **Mediation analysis**

731 The causal relationships between exposure factors, SVs and BAs were inferred by  
732 bidirectional mediation analysis with R package *mediation* (version 4.5.0). To reduce  
733 the number of tests, before mediation analysis we identified lifestyle  $\square$  SV  $\square$  BA groups  
734 in which all variables correlated with each other as candidate groups with a potential  
735 causal relationship. A candidate group had to meet the following criteria: (1) the  
736 association between the BA and SV is significant and replicable in both LLD and  
737 300-OB, (2) the association between BA and lifestyle factor is significant ( $P < 0.05$ )  
738 and (3) the association between lifestyle factor and SV is significant ( $P < 0.05$ ). We  
739 identified 1,338 candidate groups for vSVs and 175 candidate groups for dSVs. We  
740 then performed bidirectional mediation analysis on the candidate variable groups  
741 following the framework described in **Figure 6A**. For the vSV candidate groups, a  
742 linear model was used in each step of mediation analysis. For the dSV candidate  
743 groups, a logistic regression model was used when the response variable was a dSV.  
744 Finally, the P-values of indirect effects were corrected by FDR estimation.

### 745 **Distance calculation**

746 We merged the vSV and dSV profiles and calculated Canberra distance between all  
747 samples based on the SV profile of each species respectively. We then standardized  
748 all matrices by dividing each matrix by its maximum distance value. To quantify the  
749 overall microbial genetic kinships between all individuals, we calculated the  
750 metagenome-wide genetic dissimilarities between all samples by calculating the  
751 distance of shared SVs. To quantify the overall compositional differences of the BA  
752 pool, we calculated the Canberra distance between all samples based on BA  
753 concentration profile and proportion profile. Distance matrices were computed using  
754 the *vegdist()* function from R package *vegan* (version 2.5-6).

755 **Unconstrained and constrained ordination analysis**

756 We performed principal coordinates analysis (PCoA) on Canberra distance matrices  
757 of SV and BA profiles using *cmscale()* function from R package *vegan*. We estimated  
758 the proportion of BA pool variance explained by basic phenotypes (sex, age, and BMI)  
759 and cohort factor using permutational multivariate analysis of variance  
760 (PERMANOVA) with *adonis()* function from R package *vegan*. We estimated  
761 proportions of metagenome-wide SV-based genetic variance explained by age, sex,  
762 BMI and read count using PERMANOVA.

763 **Clustering analysis**

764 Based on the genetic dissimilarity matrix of each species, we clustered the samples  
765 using the partitioning around medoid method and assigned samples to clusters with a  
766 given cluster number  $k$  ( $k \in [2, 10]$ ). The best cluster numbers were determined by  
767 prediction strength (PS) (Tibshirani and Walther, 2012), with the highest number of  
768 clusters with a PS above 0.55 considered the best cluster number. If there was no PS  
769 value  $> 0.55$ , we assumed there was no obvious cluster (subspecies) within the  
770 corresponding species. The clustering results were then visualized using PCoA plot  
771 and t-distributed stochastic neighbor embedding (t-SNE) (Kobak and Berens, 2019).

772

773

774

775 **References**










776

- 777 Beghini, F., McIver, L.J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S.,  
778 Mailyan, A., Thomas, A.M., Manghi, P., Valles-Colomer, M., et al. (2020).  
779 Integrating taxonomic, functional, and strain-level profiling of diverse microbial  
780 communities with bioBakery 3. *Biorxiv* 2020.11.19.388223.
- 781 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for  
782 Illumina sequence data. *Bioinformatics* 30, 2114–2120.
- 783 Chambers, K.F., Day, P.E., Aboufarrag, H.T., and Kroon, P.A. (2019). Polyphenol  
784 Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review.  
785 *Nutrients* 11, 2588.
- 786 Chávez-Talavera, O., Tailleux, A., Lefebvre, P., and Staels, B. (2017). Bile Acid  
787 Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia,  
788 and Nonalcoholic Fatty Liver Disease. *Gastroenterology* 152, 1679-1694.e3.
- 789 Chen, L., Munckhof, I.C.L. van den, Schraa, K., Horst, R. ter, Koehorst, M., Faassen,  
790 M. van, Ley, C. van der, Doestzada, M., Zhernakova, D.V., Kurilshikov, A., et al.  
791 (2020). Genetic and Microbial Associations to Plasma and Fecal Bile Acids in  
792 Obesity Relate to Plasma Lipids and Liver Fat Content. *Cell Reports* 33, 108212.
- 793 Chiang, J.Y. (2017). Recent advances in understanding bile acid homeostasis.  
794 *F1000research* 6, 2029.
- 795 Costea, P.I., Coelho, L.P., Sunagawa, S., Munch, R., Huerta-Cepas, J., Forslund, K.,  
796 Hildebr, Falk, Kushugulova, A., Zeller, G., et al. (2017). Subspecies in the global  
797 human gut microbiome. *Mol Syst Biol* 13, 960.
- 798 Dermadi, D., Valo, S., Ollila, S., Soliymani, R., Sipari, N., Pussila, M., Sarantaus, L.,  
799 Linden, J., Baumann, M., and Nyström, M. (2017). Western Diet Deregulates Bile  
800 Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon. *Cancer Res* 77,  
801 3352–3363.
- 802 Eggink, H.M., Oosterman, J.E., Goede, P. de, Vries, E.M. de, Foppen, E., Koehorst,  
803 M., Groen, A.K., Boelen, A., Romijn, J.A., Fleur, S.E. la, et al. (2017). Complex  
804 interaction between circadian rhythm and diet on bile acid homeostasis in male rats.  
805 *Chronobiol Int* 34, 1–15.
- 806 Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov,  
807 A., Bonder, M.J., Valles-Colomer, M., Vandeputte, D., et al. (2016). Population-level  
808 analysis of gut microbiome variation. *Sci New York N Y* 352, 560–564.
- 809 Gao, L., Lv, G., Li, R., Liu, W., Zong, C., Ye, F., Li, X., Yang, X., Jiang, J., Hou, X.,  
810 et al. (2019). Glycochenodeoxycholate promotes hepatocellular carcinoma invasion  
811 and migration by AMPK/mTOR dependent autophagy activation. *Cancer Lett* 454,  
812 215–223.

- 813 Gu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., Zhang, D., Feng, Q., Xie, X.,  
814 Hong, J., et al. (2017). Analyses of gut microbiota and plasma bile acids enable  
815 stratification of patients for antidiabetic treatment. *Nat Commun* 8, 1785.
- 816 Heinken, A., Ravcheev, D.A., Baldini, F., Heirendt, L., Fleming, R.M.T., and Thiele,  
817 I. (2019). Systematic assessment of secondary bile acid metabolism in gut microbes  
818 reveals distinct metabolic capabilities in inflammatory bowel disease. *Microbiome* 7,  
819 75.
- 820 Heintz-Buschart, A., and Wilmes, P. (2018). Human Gut Microbiome: Function  
821 Matters. *Trends Microbiol* 26, 563--574.
- 822 Hoogerland, J.A., Lei, Y., Wolters, J.C., Boer, J.F., Bos, T., Bleeker, A., Mulder, N.L.,  
823 Dijk, T.H., Kuivenhoven, J.A., Rajas, F., et al. (2019). Glucose  $\square$  6  $\square$  Phosphate  
824 Regulates Hepatic Bile Acid Synthesis in Mice. *Hepatology* 70, 2171--2184.
- 825 Horst, R. ter, Munckhof, I.C.L. van den, Schraa, K., Aguirre-Gamboa, R., Jaeger, M.,  
826 Smeekens, S.P., Brand, T., Lemmers, H., Dijkstra, H., Galesloot, T.E., et al. (2019).  
827 Sex-Specific Regulation of Inflammation and Metabolic Syndrome in Obesity.  
828 *Arteriosclerosis Thrombosis Vasc Biology* 40, 1787--1800.
- 829 Jackson, M.A., Verdi, S., Maxan, M.-E., Shin, C.M., Zierer, J., Bowyer, R.C.E.,  
830 Martin, T., Williams, F.M.K., Menni, C., Bell, J.T., et al. (2018). Gut microbiota  
831 associations with common diseases and prescription medications in a population-  
832 based cohort. *Nat Commun* 9, 2655.
- 833 Jia, W., Xie, G., and Jia, W. (2017). Bile acid--microbiota crosstalk in gastrointestinal  
834 inflammation and carcinogenesis. *Nat Rev Gastroentero* 15, 111--128.
- 835 Kobak, D., and Berens, P. (2019). The art of using t-SNE for single-cell  
836 transcriptomics. *Nat Commun* 10, 5416.
- 837 Krautkramer, K.A., Fan, J., and Bäckhed, F. (2021). Gut microbial metabolites as  
838 multi-kingdom intermediates. *Nat Rev Microbiol* 19, 77--94.
- 839 Kuipers, F., Bloks, V.W., and Groen, A.K. (2014). Beyond intestinal soap--bile acids  
840 in metabolic control. *Nat Rev Endocrinol* 10, 488--498.
- 841 Kurilshikov, A., er, Munckhof, I.C.L. van den, Chen, L., Bonder, M.J., Schraa, K.,  
842 Rutten, J.H.W., Riksen, N.P., Graaf, J. de, Oosting, M., et al. (2019). Gut Microbial  
843 Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk.  
844 *Circ Res* 124, 1808--1820.
- 845 Langdon, A., Crook, N., and Dantas, G. (2016). The effects of antibiotics on the  
846 microbiome throughout development and alternative approaches for therapeutic  
847 modulation. *Genome Med* 8, 39.
- 848 Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2.  
849 *Nat Methods* 9, 357--359.

- 850 Li, R., Andreu-Sánchez, S., Kuipers, F., and Fu, J. (2021). Gut microbiome and bile  
851 acids in obesity-related diseases. *Best Pract Res Clin En* 101493.
- 852 Mars, R.A.T., Yang, Y., Ward, T., Houtti, M., Priya, S., Lekatz, H.R., Tang, X., Sun,  
853 Z., Kalari, K.R., Korem, T., et al. (2020). Longitudinal Multi-omics Reveals Subset-  
854 Specific Mechanisms Underlying Irritable Bowel Syndrome. *Cell*.
- 855 Mende, D.R., Letunic, I., Huerta-Cepas, J., Li, S.S., Forslund, K., Sunagawa, S., and  
856 Bork, P. (2017). proGenomes: a resource for consistent functional and taxonomic  
857 annotations of prokaryotic genomes. *Nucleic Acids Res* 45, D529–D534.
- 858 Naumann, S., Haller, D., Eisner, P., and Schweiggert-Weisz, U. (2020). Mechanisms  
859 of Interactions between Bile Acids and Plant Compounds—A Review. *Int J Mol Sci*  
860 21, 6495.
- 861 Ozdal, T., Sela, D.A., Xiao, J., Boyacioglu, D., Chen, F., and Capanoglu, E. (2016).  
862 The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on  
863 Bioaccessibility. *Nutrients* 8, 78.
- 864 Pathak, P., Xie, C., Nichols, R.G., Ferrell, J.M., Boehme, S., Krausz, K.W., Patterson,  
865 A.D., Gonzalez, F.J., and Chiang, J.Y.L. (2018). Intestine farnesoid X receptor  
866 agonist and the gut microbiota activate G $\alpha$  protein bile acid receptor $\alpha$ 1 signaling to  
867 improve metabolism. *Hepatology* 68, 1574–1588.
- 868 Queipo-Ortuño, M.I., Boto-Ordóñez, M., Murri, M., Gomez-Zumaquero, J.M.,  
869 Clemente-Postigo, M., Estruch, R., Diaz, F.C., Andrés-Lacueva, C., and Tinahones,  
870 F.J. (2012). Influence of red wine polyphenols and ethanol on the gut microbiota  
871 ecology and biochemical biomarkers. *Am J Clin Nutrition* 95, 1323–1334.
- 872 Rossum, T.V., Ferretti, P., Maistrenko, O.M., and Bork, P. (2020). Diversity within  
873 species: interpreting strains in microbiomes. *Nat Rev Microbiol* 1–16.
- 874 Sembries, S., Dongowski, G., Mehrländer, K., Will, F., and Dietrich, H. (2006).  
875 Physiological Effects of Extraction Juices from Apple, Grape, and Red Beet Pomaces  
876 in Rats. *J Agr Food Chem* 54, 10269–10280.
- 877 Song, Z., Cai, Y., Lao, X., Wang, X., Lin, X., Cui, Y., Kalavagunta, P.K., Liao, J., Jin,  
878 L., Shang, J., et al. (2019). Taxonomic profiling and populational patterns of bacterial  
879 bile salt hydrolase (BSH) genes based on worldwide human gut microbiome.  
880 *Microbiome* 7, 9.
- 881 Steiner, C., Othman, A., Saely, C.H., Rein, P., Drexel, H., Eckardstein, A. von, and  
882 Rentsch, K.M. (2011). Bile Acid Metabolites in Serum: Intraindividual Variation and  
883 Associations with Coronary Heart Disease, Metabolic Syndrome and Diabetes  
884 Mellitus. *Plos One* 6, e25006.
- 885 Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J.,  
886 Chen, B., et al. (2018). Gut microbiota and intestinal FXR mediate the clinical  
887 benefits of metformin. *Nat Med* 24, 1919–1929.



- 888 Tian, Y., Gui, W., Koo, I., Smith, P.B., Allman, E.L., Nichols, R.G., Rimal, B., Cai, J.,  
889 Liu, Q., and Patterson, A.D. (2020). The microbiome modulating activity of bile acids.  
890 *Gut Microbes* *11*, 1–18.
- 891 Tibshirani, R., and Walther, G. (2012). Cluster Validation by Prediction Strength. *J*  
892 *Comput Graph Stat* *14*, 511–528.
- 893 Tierney, B.T., Yang, Z., Luber, J.M., Beaudin, M., Wibowo, M.C., Baek, C.,  
894 Mehlenbacher, E., Patel, C.J., and Kostic, A.D. (2019). The Landscape of Genetic  
895 Content in the Gut and Oral Human Microbiome. *Cell Host Microbe* *26*, 283-295.e8.
- 896 Tigchelaar, E.F., Zhernakova, A., ra, Dekens, J.A.M., Hermes, G., Baranska, A.,  
897 Mujagic, Z., Swertz, M.A., Muñoz, A.M., Deelen, P., et al. (2015). Cohort profile:  
898 LifeLines DEEP, a prospective, general population cohort study in the northern  
899 Netherlands: study design and baseline characteristics. *Bmj Open* *5*, e006772.
- 900 Udayappan, S., Manneras-Holm, L., Chaplin-Scott, A., Belzer, C., Herrema, H.,  
901 Dallinga-Thie, G.M., Duncan, S.H., Stroes, E.S.G., Groen, A.K., Flint, H.J., et al.  
902 (2016). Oral treatment with *Eubacterium hallii* improves insulin sensitivity in db/db  
903 mice. *Npj Biofilms Microbiomes* *2*, 16009.
- 904 Wattam, A.R., Davis, J.J., Assaf, R., Boisvert, S., Brettin, T., Bun, C., Conrad, N.,  
905 Dietrich, E.M., Disz, T., Gabbard, J.L., et al. (2017). Improvements to PATRIC, the  
906 all-bacterial Bioinformatics Database and Analysis Resource Center. *Nucleic Acids*  
907 *Res* *45*, D535–D542.
- 908 Zeevi, D., Korem, T., Godneva, A., Bar, N., Kurilshikov, A., Lotan-Pompan, M.,  
909 Weinberger, A., Fu, J., Wijmenga, C., Zhernakova, A., et al. (2019). Structural  
910 variation in the gut microbiome associates with host health. *Nature* *568*, 43–48.
- 911 Zhernakova, A., Kurilshikov, A., Bonder, M.J., Tigchelaar, E.F., Schirmer, M.,  
912 Vatanen, T., Mujagic, Z., Vila, A.V., Falony, G., Vieira-Silva, S., et al. (2016).  
913 Population-based metagenomics analysis reveals markers for gut microbiome  
914 composition and diversity. *Science* *352*, 565–569.
- 915

**A****B****C****F****D****E****G****H****I****BAS**


- TUDCA
- GUDCA
- UDCA
- TLCA
- GLCA
- LCA
- TDCA
- GDCA
- DCA
- TGDCA
- GCDCA
- CDCA
- TCA
- GCA
- CA








**BAS**






- TUDCA\_p
- GUDCA\_p
- UDCA\_p
- TLCA\_p
- GLCA\_p
- LCA\_p
- TDCA\_p
- GDCA\_p
- DCA\_p
- TGDCA\_p
- GCDCA\_p
- CDCA\_p
- TCA\_p
- GCA\_p
- CA\_p









**A****B****D****C****E****F**